Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

American Journal of Hematology(2023)10.1002/ajh.27161Source: DataRank Database

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes is a research paper published in American Journal of Hematology (2023). On theSindex it has a DataRank of 0. It has been cited 48 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access48 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 9.06)OA: bronzeTopics (31)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (27)

Jordi Esteve ORCID,Kimmo Porkka ORCID,Steven Knapper ORCID,Elie Traer ORCID,Sebastian Scholl ORCID

Live enrichment

PubMed:37994196 OpenAlex:https://openalex.org/W4388951914

Novartis Pharmaceuticals Corporation

FWCI

9.06

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.27161

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.27161

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27161

journalhttps://doi.org/10.1002/ajh.27161

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37994196

Fields of Study

Acute Myeloid Leukemia ResearchPeptidase Inhibition and AnalysisMultiple Myeloma Research and Treatments

MeSH Terms

Hepatitis A Virus Cellular Receptor 2DecitabineAntibodiesAntibodies, MonoclonalAntimetabolites, AntineoplasticAzacitidineHumansMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicTreatment Outcome

Keywords

AzacitidineDecitabineMyelodysplastic syndromesMedicineChronic myelomonocytic leukemiaHypomethylating agentMyeloid leukemiaImmunotherapyInternal medicineInternational Prognostic Scoring SystemOncologyMyeloidAntibodyImmunologyBone marrowCancerBiology